Emcure Pharmaceuticals Ltd (EMCURE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.56 Billion ≈ $27.71 Million USD) by net assets (Rs48.84 Billion ≈ $528.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EMCURE market cap for the company's overall valuation and market capitalisation.
Emcure Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2022–2026)
This chart illustrates how Emcure Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Emcure Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emcure Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore Emcure Pharmaceuticals Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Premier Inc
NASDAQ:PINC
|
0.010x |
|
Hamilton Lane Inc
NASDAQ:HLNE
|
0.056x |
|
Galenica Sante AG
SW:GALE
|
0.129x |
|
ESAB Corp
NYSE:ESAB
|
0.021x |
|
PBF Energy Inc
NYSE:PBF
|
0.005x |
|
Axtel S.A.B. de C.V
MX:AXTELCPO
|
0.443x |
|
Algonquin Power & Utilities Corp
TO:AQN
|
0.082x |
|
Dun & Bradstreet Holdings Inc.
NYSE:DNB
|
0.023x |
Annual Cash Flow Conversion Efficiency for Emcure Pharmaceuticals Ltd (2022–2026)
The table below shows the annual cash flow conversion efficiency of Emcure Pharmaceuticals Ltd from 2022 to 2026. View EMCURE live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs49.77 Billion ≈ $538.21 Million |
Rs8.51 Billion ≈ $91.98 Million |
0.171x | -6.86% |
| 2025-03-31 | Rs46.42 Billion ≈ $501.97 Million |
Rs8.52 Billion ≈ $92.11 Million |
0.183x | -47.79% |
| 2024-03-31 | Rs31.22 Billion ≈ $337.61 Million |
Rs10.97 Billion ≈ $118.66 Million |
0.351x | +24.70% |
| 2023-03-31 | Rs26.50 Billion ≈ $286.55 Million |
Rs7.47 Billion ≈ $80.77 Million |
0.282x | -22.43% |
| 2022-03-31 | Rs21.14 Billion ≈ $228.64 Million |
Rs7.68 Billion ≈ $83.08 Million |
0.363x | -- |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more